The diagnostic yield of hereditary cancer genetic testing has improved over time as new technologies have been established. Despite these improvements, a substantial proportion of patients undergoing DNA testing for hereditary cancer still either receive inconclusive results or remain without a molecular diagnosis. This webinar will demonstrate how concurrent DNA and RNA genetic testing increases detection of clinically- actionable variants and reduces variants of unknown significance (VUS), ultimately improving the positive yield of genetic testing.
Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.
Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.